NATCO Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−7.9%+10.8%+47.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−34.6%+25.4%+87.2%
−37.3%+25.3%+102.7%
−24.7%+35.7%+94.1%
−24.8%+36.1%+97.4%
+28.3%+25.0%+22.1%
+21.1%+30.1%+20.1%
+4.2%+40.0%+42.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCOPHARM₹787.55

NATCO Pharma Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,097 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+47.7+10.8-7.9—
EBITDA Growth—+87.2+25.4-34.6—
EBIT Growth—+102.7+25.3-37.3—
Net Income Growth—+94.1+35.7-24.7—
EPS Growth—+97.4+36.1-24.8—
Total Assets Growth—+22.1+25.0+28.3—
Total Equity Growth—+20.1+30.1+21.1—
Cash from Operations Growth—+42.7+40.0+4.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.